Well, we heard yesterday from the Poseidon that actually there is a limited role for ADT in patients with a PSA below 0.5. Although there was some pushback, especially in younger patients and higher risk patients, a lot of participants argued that there might still be a role for ADT in combination with salvage radiotherapy but also a major takeaway was that we need to have smarter drugs and also look at genomic profiling like for instance the PAM50 signature or the Decipher tests that could guide us towards a really smart implementation of ADT and also replacing ADT with RC or RP monotherapy like in the SAFE trial...
Well, we heard yesterday from the Poseidon that actually there is a limited role for ADT in patients with a PSA below 0.5. Although there was some pushback, especially in younger patients and higher risk patients, a lot of participants argued that there might still be a role for ADT in combination with salvage radiotherapy but also a major takeaway was that we need to have smarter drugs and also look at genomic profiling like for instance the PAM50 signature or the Decipher tests that could guide us towards a really smart implementation of ADT and also replacing ADT with RC or RP monotherapy like in the SAFE trial. And we have recently amended the trial to also collect long-term oncological outcomes, metastasis-free survival, and we will incorporate PSMA PET because in Belgium it is the standard treatment with a rising PSA to do a PSMA PET. So I believe we will quickly have data on the MFS survival and we can hopefully show that apalutamide monotherapy is just as good as ADT in the long term as well.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
